CAPRICOR THERAPEUTICS, INC. Cash Flow Statement
CAPR / Health Care|15 years of annual SEC 10-K data (FY2011-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 15 fiscal years. All figures from audited SEC 10-K filings.
CAPRICOR THERAPEUTICS, INC. used $70M in operating cash flow and negative free cash flow of $73M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$105.0M | -$40.5M | -$22.3M | -$29.0M | -$20.0M | -$13.7M | -$15.2M | -$15.2M | $2.4M | -$18.8M | -$12.9M | -$6.2M | -$8.9M | -$2.1M | -$1.1M |
| Depreciation & Amortization | $1.9M | $1.4M | $1.1M | $533.1K | $245.7K | $143.9K | $157.7K | $157.7K | $144.2K | $125.7K | $110.9K | $41.9K | $26.9K | $20.3K | $7.5K |
| Operating Cash Flow | -$69.8M | -$40.0M | -$25.6M | $4.9M | -$16.8M | -$10.1M | -$13.9M | -$13.9M | -$14.2M | -$14.5M | -$10.8M | $958.6K | -$6.1M | -$34.9M | -$4.6M |
| Capital Expenditures | $2.9M | $1.2M | $1.3M | $2.0M | $1.2M | $547.6K | $316.5K | $316.5K | $32.2K | $192.0K | $129.7K | $162.7K | $56.1K | $13.4K | $2.0K |
| Free Cash Flow | -$72.7M | -$41.2M | -$26.9M | $2.9M | -$18.0M | -$10.6M | -$14.2M | -$14.2M | -$14.3M | -$14.6M | -$10.9M | $795.9K | -$6.2M | -$34.9M | -$4.7M |
| Share Buybacks | - | - | - | - | - | $0 | $0 | $0 | - | - | - | - | - | - | - |
| FCF Margin | - | -184.8% | -106.9% | 114.3% | -7352.3% | -3417.4% | -848.3% | -848.3% | -534.9% | -366.3% | -198.4% | 16.6% | - | -1717.5% | -343.4% |